Journal
JOURNAL OF INVESTIGATIVE DERMATOLOGY
Volume 128, Issue 11, Pages 2596-2605Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/jid.2008.101
Keywords
-
Categories
Funding
- German Research Foundation (DFG)
- NIH
Ask authors/readers for more resources
Immunotherapy for melanoma has undergone significant change since the first attempts to treat patients with high dose IL-2. Herein, strategies to boost patient antitumor immunity through vaccination, treatment with agents that augment host immunity, and adoptive cell transfer will be discussed. The first two strategies have yielded only limited clinical success, but adoptive cell transfer therapy, particularly following a lymphodepleting, preconditioning regimen has resulted in objective response rates approaching 50%. For a number of reasons, lymphodepletion appears to be critical for maintenance of circulating antitumor T cells following adoptive cell transfer. Balancing antitumor efficacy, autoimmunity, and reconstitution of a functioning immune system remain challenging and potentially life-threatening issues.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available